BAX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and systemic defects in its Novum IQ Large Volume Pump, which have resulted in significant patient risks and a notable decline in stock price [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc." and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter and its executives violated the Securities Exchange Act of 1934 by making false statements and failing to disclose critical information regarding the Novum LVP [3]. Group 2: Allegations Against Baxter - The lawsuit claims that the Novum LVP had systemic defects leading to malfunctions such as underinfusion and overinfusion, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures [3]. - On July 31, 2025, Baxter announced a voluntary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in the company's stock price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].